420 related articles for article (PubMed ID: 30507740)
1. Subclinical Antibody-mediated Rejection After Kidney Transplantation: Treatment Outcomes.
Parajuli S; Joachim E; Alagusundaramoorthy S; Blazel J; Aziz F; Garg N; Muth B; Mohamed M; Mandelbrot D; Zhong W; Djamali A
Transplantation; 2019 Aug; 103(8):1722-1729. PubMed ID: 30507740
[TBL] [Abstract][Full Text] [Related]
2. Treatment of Biopsy-Proven Acute Antibody-Mediated Rejection Using Thymoglobulin (ATG) Monotherapy and a Combination of Rituximab, Intravenous Immunoglobulin, and Plasmapheresis: Lesson Learned from Primary Experience.
Zheng J; Xue W; Qing X; Jing X; Hou J; Tian X; Guo Q; He X; Cai J
Clin Transpl; 2014; ():223-30. PubMed ID: 26281149
[TBL] [Abstract][Full Text] [Related]
3. De Novo Anti-HLA DSA Characteristics and Subclinical Antibody-Mediated Kidney Allograft Injury.
Yamamoto T; Watarai Y; Takeda A; Tsujita M; Hiramitsu T; Goto N; Narumi S; Katayama A; Morozumi K; Uchida K; Kobayashi T
Transplantation; 2016 Oct; 100(10):2194-202. PubMed ID: 26636737
[TBL] [Abstract][Full Text] [Related]
4. Durable renal response after combination of bortezomib, corticosteroids, rituximab, and plasmapheresis for late antibody-mediated renal transplant rejection
.
Ding Y; Francis J; Gautam A; Pelletier L; Sanchorawala V; Quillen K
Clin Nephrol; 2018 Apr; 89(4):252-259. PubMed ID: 29208204
[TBL] [Abstract][Full Text] [Related]
5. Characteristics of Circulating Donor Human Leukocyte Antigen-specific Immunoglobulin G Antibodies Predictive of Acute Antibody-mediated Rejection and Kidney Allograft Failure.
Kannabhiran D; Lee J; Schwartz JE; Friedlander R; Aull M; Muthukumar T; Campbell S; Epstein D; Seshan SV; Kapur S; Sharma VK; Suthanthiran M; Dadhania D
Transplantation; 2015 Jun; 99(6):1156-64. PubMed ID: 25629531
[TBL] [Abstract][Full Text] [Related]
6. Protocol Biopsies in Patients With Subclinical De Novo Donor-specific Antibodies After Kidney Transplantation: A Multicentric Study.
Bertrand D; Gatault P; Jauréguy M; Garrouste C; Sayegh J; Bouvier N; Caillard S; Lanfranco L; Galinier A; Laurent C; Etienne I; Farce F; François A; Guerrot D
Transplantation; 2020 Aug; 104(8):1726-1737. PubMed ID: 32732853
[TBL] [Abstract][Full Text] [Related]
7. Impact of active antibody-mediated rejection treatment on donor-specific antibodies in pediatric kidney transplant recipients.
Kincaide E; Hitchman K; Hall R; Yamaguchi I; Ding Y; Crowther B
Pediatr Transplant; 2019 Dec; 23(8):e13590. PubMed ID: 31617318
[TBL] [Abstract][Full Text] [Related]
8. Clinical Relevance of Posttransplant DSAs in Patients Receiving Desensitization for HLA-incompatible Kidney Transplantation.
Vo AA; Aubert O; Haas M; Huang E; Zhang X; Choi J; Peng A; Najjar R; Sethi S; Ammerman N; Lim K; Jordan SC
Transplantation; 2019 Dec; 103(12):2666-2674. PubMed ID: 30883456
[TBL] [Abstract][Full Text] [Related]
9. Mid-Term Outcomes After Treatment for Antibody-Mediated Rejection by De Novo Donor-Specific HLA Antibody in Renal Transplant Recipients: Does Early Treatment Lead to Better Outcomes?
Okada M; Tomosugi T; Futamura K; Hiramitsu T; Goto N; Narumi S; Takeda A; Watarai Y
Transplant Proc; 2020 Dec; 52(10):3051-3057. PubMed ID: 32694058
[TBL] [Abstract][Full Text] [Related]
10. Outcome of Desensitization Therapy in Immunologically High-Risk Kidney Transplantation: Single-Center Experience.
Sinangil A; Ucar ZA; Koc Y; Barlas S; Abouzahir S; Ecder ST; Akin EB
Transplant Proc; 2019 Sep; 51(7):2268-2273. PubMed ID: 31358450
[TBL] [Abstract][Full Text] [Related]
11. Failure to remove de novo donor-specific HLA antibodies is influenced by antibody properties and identifies kidney recipients with late antibody-mediated rejection destined to graft loss - a retrospective study.
Cioni M; Nocera A; Tagliamacco A; Basso S; Innocente A; Fontana I; Magnasco A; Trivelli A; Klersy C; Gurrado A; Ramondetta M; Boghen S; Catenacci L; Verrina E; Garibotto G; Ghiggeri GM; Cardillo M; Ginevri F; Comoli P
Transpl Int; 2019 Jan; 32(1):38-48. PubMed ID: 30076765
[TBL] [Abstract][Full Text] [Related]
12. Clinical Significance of Microvascular Inflammation in the Absence of Anti-HLA DSA in Kidney Transplantation.
Parajuli S; Redfield RR; Garg N; Aziz F; Mohamed M; Astor BC; Zhong W; Djamali A; Mandelbrot DA
Transplantation; 2019 Jul; 103(7):1468-1476. PubMed ID: 30335696
[TBL] [Abstract][Full Text] [Related]
13. Clearance of Intra-graft Donor Specific Anti-HLA Antibodies in the Early Stage of Antibody-Mediated Rejection Following Rituximab and Apheresis Therapy in Renal Transplantation.
Nakamura T; Yoshimura N; Akioka K; Shirouzu T; Kawai S; Imanishi Y; Matsuyama T; Harada S; Nobori S; Ushigome H
Transplant Proc; 2019 Jun; 51(5):1365-1370. PubMed ID: 31056246
[TBL] [Abstract][Full Text] [Related]
14. Long-term results of desensitization protocol with and without rituximab in sensitized kidney transplant recipients.
Green H; Nesher E; Aizner S; Israeli M; Klein T; Zakai H; Rahamimov R; Rozen-Zvi B; Mor E
Clin Transplant; 2019 Jun; 33(6):e13562. PubMed ID: 30941818
[TBL] [Abstract][Full Text] [Related]
15. Outcomes of Prolonged Treatment With Intravenous Immunoglobulin Infusions for Acute Antibody-mediated Rejection in Kidney Transplant Recipients.
Bujnowska A; Michon M; Konopelski P; Hryniewiecka E; Jalbrzykowska A; Perkowska-Ptasinska A; Cieciura T; Zagozdzon R; Paczek L; Ciszek M
Transplant Proc; 2018; 50(6):1720-1725. PubMed ID: 29961551
[TBL] [Abstract][Full Text] [Related]
16. Combination of Total Lymphoid Irradiation, Low-Dose IVIG and ATG as Rescue Therapy for Highly Sensitized and Antibody-Mediated Rejection Renal Transplant Recipients.
Zhu D; Qi G; Tang Q; Li L; Yang C; Lin M; Wu B; Xu M; Cai J; Zhu T; Rong R
Clin Transpl; 2014; ():215-21. PubMed ID: 26281148
[TBL] [Abstract][Full Text] [Related]
17. Frequent development of subclinical chronic antibody-mediated rejection within 1 year after renal transplantation with pre-transplant positive donor-specific antibodies and negative CDC crossmatches.
Yamanaga S; Watarai Y; Yamamoto T; Tsujita M; Hiramitsu T; Nanmoku K; Goto N; Takeda A; Morozumi K; Katayama A; Saji H; Uchida K; Kobayashi T
Hum Immunol; 2013 Sep; 74(9):1111-8. PubMed ID: 23792054
[TBL] [Abstract][Full Text] [Related]
18. Determining donor-specific antibody C1q-binding ability improves the prediction of antibody-mediated rejection in human leucocyte antigen-incompatible kidney transplantation.
Malheiro J; Tafulo S; Dias L; Martins S; Fonseca I; Beirão I; Castro-Henriques A; Cabrita A
Transpl Int; 2017 Apr; 30(4):347-359. PubMed ID: 27717025
[TBL] [Abstract][Full Text] [Related]
19. Quantifying renal allograft loss following early antibody-mediated rejection.
Orandi BJ; Chow EH; Hsu A; Gupta N; Van Arendonk KJ; Garonzik-Wang JM; Montgomery JR; Wickliffe C; Lonze BE; Bagnasco SM; Alachkar N; Kraus ES; Jackson AM; Montgomery RA; Segev DL
Am J Transplant; 2015 Feb; 15(2):489-98. PubMed ID: 25611786
[TBL] [Abstract][Full Text] [Related]
20. Indicators of treatment responsiveness to rituximab and plasmapheresis in antibody-mediated rejection after kidney transplantation.
Immenschuh S; Zilian E; Dämmrich ME; Schwarz A; Gwinner W; Becker JU; Blume CA
Transplantation; 2015 Jan; 99(1):56-62. PubMed ID: 25121474
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
